SciELO - Scientific Electronic Library Online

 
vol.44 número2Sistema Inmune, Infección por SARS-CoV-2 y Desarrollo de COVID-19Tratamiento Combinado en Leishmaniasis Cutánea con Falla Terapéutica índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Gaceta Médica Boliviana

versión impresa ISSN 1012-2966versión On-line ISSN 2227-3662

Resumen

HUANCA HUANCA, María Luz; CALDERON LOPEZ, Maria Elena; ROJAS CABRERA, Ernesto  y  SAAVEDRA BORDA, Carmen Rocío. Liposomal Amphotericin B, Pediatric Treatment of Cutaneous Leishmaniasis with Therapeutic Failure. Gac Med Bol [online]. 2021, vol.44, n.2, pp.254-259. ISSN 1012-2966.  https://doi.org/10.47993/gmb.v44i2.320.

The cutaneous leishmaniasis in Bolivia is less frequent in children. Its presence probably responds to the domestication of the vector in areas of human settlements. Amphotericin B is indicated for the treatment of leishmaniasis in adults, without response to pentavalent antimonials or without a clinical cure for ulcers. The objective of this series of cases is to share experiences of the use of liposomal amphotericin B in paediatric patients with cutaneous leishmaniasis and therapeutic failure of antimonials. Six patients with these characteristics admitted to the Infectology service of the Manuel Asencio Villarroel paediatric hospital, received liposomal Amphotericin B, 2 to 3 mg / kg weight day, in a mean period of 18 days. Progressive remission of the ulcers was observed during treatment and complete healing at three months of post-treatment. None had adverse effects, and the kidney and liver biochemical tests were within normal values.

Palabras clave : leishmaniasis cutaneous; amphotericin B; eficacy; treatment outcome.

        · resumen en Español     · texto en Español     · Español ( pdf )